Endless Ark, an AI-driven biopharmaceutical company, has secured tens of millions in a seed funding round led by Monolith Ventures. The company, founded by Oxford PhD student Zhao Simiao, focuses on developing longevity drugs and therapies for organ function improvement using cross-species AI models. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
IMPACT This funding could accelerate the development of AI-driven longevity drugs, potentially impacting future healthcare and pharmaceutical research.
RANK_REASON Significant funding round for an AI-focused biotech company. [lever_c_demoted from significant: ic=1 ai=0.7]